Litigation Details for PAR PHARMACEUTICAL, INC. v. SANDOZ INC. (D.N.J. 2018)
✉ Email this page to a colleague
PAR PHARMACEUTICAL, INC. v. SANDOZ INC. (D.N.J. 2018)
| Docket | ⤷ Try a Trial | Date Filed | 2018-10-11 |
| Court | District Court, D. New Jersey | Date Terminated | |
| Cause | 15:1126 Patent Infringement | Assigned To | Brian R. Martinotti |
| Jury Demand | Defendant | Referred To | Douglas Arpert |
| Parties | SANDOZ INC. | ||
| Patents | 9,375,478; 9,687,526; 9,744,209; 9,744,239; 9,750,785; 9,937,223 | ||
| Attorneys | CHRISTINA LYNN SAVERIANO | ||
| Firms | Brian M. Goldberg | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in PAR PHARMACEUTICAL, INC. v. SANDOZ INC.
The small molecule drug covered by the patents cited in this case is ⤷ Try a Trial .
Details for PAR PHARMACEUTICAL, INC. v. SANDOZ INC. (D.N.J. 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2018-10-11 | 1 | United States Patent Nos. 9,375,478 (“the ‘478 Patent”), 9,687,526 (“the ‘526 Patent”), 9,744,209 (“…(“the ‘209 Patent”), 9,744,239 (“the ‘239 Patent”), 9,750,785 (“the ‘785 Patent”), and 9,937,223 (“the…the ‘223 Patent”) (collectively, “the Patents-in-Suit”). This action is based upon the Patent Laws of … The Patents-in-Suit 14. On June 28, 2016, the United States Patent and Trademark…copy of the ‘478 Patent is attached as Exhibit A. Par Pharmaceutical owns the ‘478 Patent. 15. | External link to document | |
| 2020-03-09 | 107 | Opinion | The patents-in-suit are U.S. Patent Nos. 9,375,478 (“’478 patent”), 9,687,526 (“’526 patent”), 9,…9,750,785 (“’785 patent”), 9,744,209 (“’209 patent”), and 9,937,223 (“’223 patent”) (collectively, the… the “patents-in-suit”). They are all from the same patent family and are continuations or continuations-in-part…, and defenses relating to U.S. Patent No. 9,744,239 (“’239 patent”). (ECF No. 90.) …United States Patent and Trademark Office (“PTO”) duly and legally issued all five patents-in-suit, each | External link to document |
| 2020-03-09 | 108 | Order | ,744,209 (“’209 patent”), and 9,937,223 (“’223 patent”) (collectively, the “patents-in-suit”): “administering…U.S. Patent Nos. 9,375,478 (“’478 patent”), 9,687,526 (“’526 patent”), 9,750,785 (“’785 patent”), 9,…2018 24 June 2020 3:18-cv-14895 835 Patent - Abbreviated New Drug Application(ANDA) Defendant | External link to document |
| 2018-11-08 | 8 | United States Patent Nos. 9,375,478 (“the ‘478 Patent”), 9,687,526 (“the ‘526 Patent”), 9,744,209 (“…(“the ‘209 Patent”), 9,744,239 (“the ‘239 Patent”), 9,750,785 (“the ‘785 Patent”), and 9,937,223 (“the…the ‘223 Patent”) (collectively, “the Patents-in-Suit”). This action is based upon the Patent Laws of … The Patents-in-Suit 14. On June 28, 2016, the United States Patent and Trademark…copy of the ‘478 Patent is attached as Exhibit A. Par Pharmaceutical owns the ‘478 Patent. | External link to document | |
| 2020-02-04 | 91 | Stipulation and Order | parties in these actions relating to U.S. Patent No. 9,744,239 shall be dismissed as per this order. Signed…2018 24 June 2020 3:18-cv-14895 835 Patent - Abbreviated New Drug Application(ANDA) Defendant | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
